title: Labor induction post-term with 25 micrograms vs. 50 micrograms of intravaginal misoprostol.
abstract: OBJECTIVE
  To compare the effectiveness of 25 microg vs. 50 microg of intravaginal misoprostol for cervical ripening and labor induction beyond 41 weeks' gestation.
  
  
  METHODS
  The study population consisted of 120 women not in active labor with a gestational age >41 weeks, singleton pregnancy with vertex presentation, reactive fetal heart rate tracing, amniotic fluid index >/=5, and Bishop score <5. Women were randomized to receive either 25 microg (n=60) or 50 microg (n=60) of intravaginal misoprostol. The dose was repeated every 4 h (maximum number of doses limited to six) until the patient exhibited three contractions in 10 min. The main outcome measure was the induction-vaginal delivery interval.
  
  
  RESULTS
  There was no significant difference between the two groups with regard to the induction-vaginal delivery interval (685+/-201 min in the 25 microg group vs. 627+/-177 min in the 50 microg group, P=0.09). The proportion of women delivering vaginally with one dose of vaginal misoprostol was significantly greater in the 50 microg group (0/49 vs. 41/47, P<0.001). There were no differences in the rates of cesarean and operative vaginal delivery rates, or in the incidences of tachysystole and hyperstimulation syndrome in the two treatment groups. Neonatal outcomes were also similar.
  
  
  CONCLUSIONS
  Intravaginal administration of 25 microg of misoprostol appears to be as effective as 50 microg for cervical ripening and labor induction beyond 41 weeks' gestation.
authors.affiliation: Department of Obstetrics and Gynecology, Turgut Ozal Medical Centre, School of Medicine, Inonu University, Malatya, Turkey. mmeydanli@inonu.edu.tr
authors.forename: M M
authors.initials: MM
authors.lastname: Meydanli
authors.forename: E
authors.initials: E
authors.lastname: Calişkan
authors.forename: F
authors.initials: F
authors.lastname: Burak
authors.forename: M A
authors.initials: MA
authors.lastname: Narin
authors.forename: R
authors.initials: R
authors.lastname: Atmaca
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D020070:Cervical Ripening / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007233:Infant, Postmature; D007751:Labor, Induced; D016595:Misoprostol / Q000008:administration & dosage* / Q000627:therapeutic use*; D010120:Oxytocics / Q000008:administration & dosage* / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011263:Pregnancy Trimester, Third / Q000187:drug effects*; D013997:Time Factors
chemical_list: D010120:Oxytocics; D016595:Misoprostol